|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122728 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-16 17:46:00 |
|
注册时间: Date of Registration: |
2026-04-16 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于多中心临床数据的高甘油三酯性急性胰腺炎重症化早期预测模型的构建与验证 |
|
Public title: |
Development and Validation of an Early Prediction Model for Severe Hypertriglyceridemic Acute Pancreitis Based on Multicenter Clinical Data |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于多中心临床数据的高甘油三酯性急性胰腺炎重症化早期预测模型的构建与验证 |
|
Scientific title: |
Development and Validation of an Early Prediction Model for Severe Hypertriglyceridemic Acute Pancreitis Based on Multicenter Clinical Data |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘子雨 |
研究负责人: |
刘子雨 |
|
Applicant: |
Liu Ziyu |
Study leader: |
Liu Ziyu |
|
申请注册联系人电话: Applicant telephone: |
+86 10 8319 8899 |
研究负责人电话: Study leader's telephone: |
+86 10 83198899 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yuzijiang333@126.com |
研究负责人电子邮件: Study leader's E-mail: |
yuzijiang333@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市西城区长椿街45号 |
研究负责人通讯地址: |
北京市西城区长椿街45号 |
|
Applicant address: |
No. 45, Changchun Street, Xicheng District, Beijing |
Study leader's address: |
No. 45, Changchun Street, Xicheng District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学宣武医院 |
||
|
Applicant's institution: |
Xuanwu Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学宣武医院 |
||
|
Affiliation of the Leader: |
Xuanwu Hospital, Capital Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
临研审[2025]461号-001 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学宣武医院伦理委员会-C |
||
|
Name of the ethic committee: |
Ethics Committee of Xuanwu Hospital Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-02 00:00:00 |
||
|
伦理委员会联系人: |
张卓然 |
||
|
Contact Name of the ethic committee: |
Zhang Zhuoran |
||
|
伦理委员会联系地址: |
北京市西城区长椿街45号 |
||
|
Contact Address of the ethic committee: |
No. 45, Changchun Street, Xicheng District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 83199270 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xwzhuoranzhang@163.com |
|
研究实施负责(组长)单位: |
首都医科大学宣武医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xuanwu Hospital Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区长椿街45号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 45, Changchun Street, Xicheng District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-financed |
||||||||||||||||||||||
|
Target disease: |
hypertriglyceridemic acute pancreatitis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
诊断试验诊断准确性 |
||||||||||||||||||||||
|
Study design: |
Diagnostic test for accuracy |
||||||||||||||||||||||
|
研究目的: |
构建并验证一个基于多中心临床数据的高甘油三酯性急性胰腺炎重症化早期预测模型,用于入院24小时内的风险分层与临床决策支持。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to construct and validate an early prediction model, utilizing multicenter clinical data, for severe hypertriglyceridemic acute pancreatitis. The model is intended to facilitate risk stratification and support clinical decision-making within the first 24 hours of admission. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 明确诊断为急性胰腺炎; 2. 年龄:>=18 岁; 3. 男女不限 4. 急性胰腺炎(AP)确诊:符合修订亚特兰大标准(任意 2 条): (1) 典型上腹痛; (2) 血清淀粉酶或脂肪酶 >=正常上限的 3 倍; (3) 影像学符合急性胰腺炎表现。 5. 病因判定为高甘油三酯性(HTG-AP):满足以下其一,并排除其他主导病因: (1) 入院时或发病早期血清甘油三酯(TG)>=11.3 mmol/L(>=1000 mg/dL); (2) 5.65–11.29 mmol/L(500–999 mg/dL)且具备乳糜血清、临床排除胆源性/酒精等主导病因,综合判断 HTG 为主要致病因素。 6. 临床资料完整,包括:预测因子采集可在 T0=入院后 0–24 小时内完成(生命体征、常规实验室检查:血常规、肝肾功能、炎症指标、脂质谱、影像学检查等)。 7. 病历资料完整. |
||||||||||||||||||||||
|
Inclusion criteria |
1. Clear diagnosis of acute pancreatitis; 2. Age: >=18 years; 3. No gender restriction; 4. Confirmed diagnosis of acute pancreatitis (AP): meeting any 2 of the revised Atlanta criteria: (1) Typical upper abdominal pain; (2) Serum amylase or lipase >= 3 times the upper limit of normal; (3) Imaging consistent with acute pancreatitis. 5. Etiology determined as hypertriglyceridemic (HTG-AP): meets one of the following and excludes other primary causes: (1) Serum triglycerides (TG) >=11.3 mmol/L (>=1000 mg/dL) at admission or early in the disease; (2) 5.65–11.29 mmol/L (500–999 mg/dL) with presence of chylous serum, and clinical exclusion of biliary/alcoholic or other primary causes, comprehensively judged that HTG is the main pathogenic factor. 6. Complete clinical data, including: collection of predictors can be completed within T0 = 0–24 hours after admission (vital signs, routine laboratory tests: blood routine, liver and kidney function, inflammatory markers, lipid profile, imaging examinations, etc.). 7. Complete medical records. |
||||||||||||||||||||||
|
排除标准: |
1.严重合并症导致的器官衰竭; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Organ failure attributed to severe comorbidities; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-02 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-04-16 00:00:00 至 To 2026-06-30 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究为回顾性研究,数据采集基于统一设计的电子病例报告表(eCRF),直接从各参与中心的医院信息系统(HIS)和实验室信息系统中提取。数据管理使用Microsoft Excel和专业统计软件(SPSS, R) 进行。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This is a retrospective study. Data were extracted from the Hospital Information System (HIS) and Laboratory Information System of each participating center using a standardized electronic Case Report Form (eCRF). Data management was performed using Microsoft Excel and professional statistical software (SPSS, R). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |